These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11585969)

  • 1. Answering patients' needs: oral alternatives to intravenous therapy.
    Borner M; Scheithauer W; Twelves C; Maroun J; Wilke H
    Oncologist; 2001; 6 Suppl 4():12-6. PubMed ID: 11585969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
    Ward S; Kaltenthaler E; Cowan J; Brewer N
    Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
    Twelves C; Gollins S; Grieve R; Samuel L
    Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral fluoropyrimidines: a closer look at their toxicities.
    Macdonald JS
    Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral therapy for colorectal cancer: how to choose.
    Damjanov N; Meropol NJ
    Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
    Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
    Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
    Prescrire Int; 2002 Apr; 11(58):44-7. PubMed ID: 11987311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
    Cunningham D; James RD
    Eur J Cancer; 2001 May; 37(7):826-34. PubMed ID: 11313169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oral fluorouracil prodrugs.
    Pazdur R; Hoff PM; Medgyesy D; Royce M; Brito R
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):48-51. PubMed ID: 9830626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal cancer: chemotherapy treatment overview.
    Royce ME; Medgyesy D; Zukowski TH; Dwivedy S; Hoff PM; Pazdur R
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):40-6. PubMed ID: 11200148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoropyrimidines: a critical evaluation.
    Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
    Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical considerations in the use of oral fluoropyrimidines.
    Hoff PM
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oral chemotherapy agents.
    Royce ME; Hoff PM; Pazdur R
    Curr Oncol Rep; 2000 Jan; 2(1):31-7. PubMed ID: 11122822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience.
    Lima AP; del Giglio A
    Eur J Cancer Care (Engl); 2005 May; 14(2):151-4. PubMed ID: 15842464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer.
    Pfeiffer P; Mortensen JP; Bjerregaard B; Eckhoff L; Sch√łnnemann K; Sandberg E; Aabo K; Jakobsen A
    Eur J Cancer; 2006 Nov; 42(16):2738-43. PubMed ID: 17011184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of fluoropyrimidine therapy: from intravenous to oral.
    Hoff PM; Cassidy J; Schmoll HJ
    Oncologist; 2001; 6 Suppl 4():3-11. PubMed ID: 11585968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fluoropyrimidines in the treatment of colorectal cancer.
    Meropol NJ
    Eur J Cancer; 1998 Sep; 34(10):1509-13. PubMed ID: 9893621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.